Sang-Won Kim1, Ji Woon Yea2, Jae Hwang Kim3, Mi Jin Gu4, Min Kyu Kang5. 1. Department of Radiation Oncology, Konyang University College of Medicine, 158 Gwanjeodong-ro, Daejeon, 35365, Republic of Korea. 2. Department of Radiation Oncology, Yeungnam University College of Medicine, 170 Hyeonchung-ro, Nam-gu, Daegu, 42415, Republic of Korea. 3. Department of Surgery, Yeungnam University College of Medicine, 170 Hyeonchung-ro, Nam-gu, Daegu, 42415, Republic of Korea. 4. Department of Pathology, Yeungnam University College of Medicine, 170 Hyeonchung-ro, Nam-gu, Daegu, 42415, Republic of Korea. 5. Department of Radiation Oncology, Kyungpook National University School of Medicine, 807 Hoguk-ro, Buk-gu, Daegu, 41404, Republic of Korea. mkkang@knu.ac.kr.
Abstract
BACKGROUND: This study investigated the role of hyperthermia combined with preoperative concurrent chemoradiotherapy (CCRT) for locally advanced rectal cancer (LARC) according to hypoxic marker expression. METHODS: One hundred and nine LARC patients with tissue blocks available for immunohistochemical assessment of carbonic anhydrase 9 (CA9) expression were reviewed. CA9 expression was considered positive when the staining percentage of tumor cells was >25% (n = 31). Pelvic radiotherapy with a total dose of 39.6-45 Gy was delivered concurrently with fluorouracil-based chemotherapy. Hyperthermia was administered to 52 patients twice a week during CCRT. Treatment response and outcomes were compared between hyperthermochemoradiotherapy (HCRT) and CCRT groups. RESULTS: In patients with positive CA9 expression, the rates of downstaging (p = 0.060) and pathologic complete response (p = 0.064) tended to be higher in the HCRT group than in the CCRT group. Distant metastasis-free survival (p = 0.029) and cancer-specific survival (p = 0.020) were significantly worse in tumors with both positive CA9 expression and poor tumor response. Negative CA9 expression, presence of major tumor response, and the use of hyperthermia were significant favorable prognostic factors for cancer-specific survival after the first recurrence in multivariate analysis. CONCLUSIONS: Hyperthermia might selectively enhance the preoperative treatment response in LARC with positive CA9 expression and offset the negative effect of hypoxia on prognosis. Pretreatment evaluation of hypoxia could aid in the selection of patients who might benefit from hyperthermia.
BACKGROUND: This study investigated the role of hyperthermia combined with preoperative concurrent chemoradiotherapy (CCRT) for locally advanced rectal cancer (LARC) according to hypoxic marker expression. METHODS: One hundred and nine LARC patients with tissue blocks available for immunohistochemical assessment of carbonic anhydrase 9 (CA9) expression were reviewed. CA9 expression was considered positive when the staining percentage of tumor cells was >25% (n = 31). Pelvic radiotherapy with a total dose of 39.6-45 Gy was delivered concurrently with fluorouracil-based chemotherapy. Hyperthermia was administered to 52 patients twice a week during CCRT. Treatment response and outcomes were compared between hyperthermochemoradiotherapy (HCRT) and CCRT groups. RESULTS: In patients with positive CA9 expression, the rates of downstaging (p = 0.060) and pathologic complete response (p = 0.064) tended to be higher in the HCRT group than in the CCRT group. Distant metastasis-free survival (p = 0.029) and cancer-specific survival (p = 0.020) were significantly worse in tumors with both positive CA9 expression and poor tumor response. Negative CA9 expression, presence of major tumor response, and the use of hyperthermia were significant favorable prognostic factors for cancer-specific survival after the first recurrence in multivariate analysis. CONCLUSIONS:Hyperthermia might selectively enhance the preoperative treatment response in LARC with positive CA9 expression and offset the negative effect of hypoxia on prognosis. Pretreatment evaluation of hypoxia could aid in the selection of patients who might benefit from hyperthermia.
Authors: J van der Zee; D González González; G C van Rhoon; J D van Dijk; W L van Putten; A A Hart Journal: Lancet Date: 2000-04-01 Impact factor: 79.321
Authors: Steven A Lee-Kong; Jeannine A Ruby; David B Chessin; Salvatore Pucciarelli; Jinru Shia; Elyn R Riedel; Donato Nitti; José G Guillem Journal: Dis Colon Rectum Date: 2012-09 Impact factor: 4.585
Authors: Laurence Goethals; Annelies Debucquoy; Christiaan Perneel; Karel Geboes; Nadine Ectors; Harlinde De Schutter; Freddy Penninckx; William H McBride; Adrian C Begg; Karin M Haustermans Journal: Int J Radiat Oncol Biol Phys Date: 2006-05-01 Impact factor: 7.038
Authors: Danielle F M De Haas-Kock; Jeroen Buijsen; Madelon Pijls-Johannesma; Ludy Lutgens; Guido Lammering; Ghislaine A P G van Mastrigt; Dirk K M De Ruysscher; Philippe Lambin; Jacoba van der Zee Journal: Cochrane Database Syst Rev Date: 2009-07-08